2,687 results match your criteria Pharmacogenomics [Journal]


Genome-wide association studies of therapeutic response: addressing the complexities.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0204DOI Listing
February 2019

Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Aim: Treatment and prevention of mother-to-child transmission of HIV in pregnancy utilizes tenofovir (TFV) and emtricitabine (FTC) as NRTI backbone in combination with a third agent from a different class. We hypothesized that combined effect of pregnancy and pharmacogenetics significantly changes TFV and FTC pharmacokinetics (PK). Therefore, this study aims to evaluate the role of SNPs of transporters (ABCC2 and ABCC4) on TFV and FTC PK during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0111DOI Listing
February 2019
3.218 Impact Factor

Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.

Aim: This study aimed to establish a population pharmacokinetic (PPK) model in Chinese patients with chronic myeloid leukemia, and to quantify the effects of pharmacogenetics on pharmacokinetic parameters of imatinib.

Methods: A total of 229 plasma concentrations from 170 patients were analyzed. Nonlinear mixed effect model was used to establish the PPK model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0139DOI Listing
February 2019

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK.

Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0188DOI Listing
February 2019

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.

Aim: We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin.

Materials & Methods: Genotypes for SLCO1B1, NAT2, PXR, ABCB1 and UGT1A genes were determined using a TaqMan Genotyping OpenArray™. Nonlinear mixed-effects models were used to describe drug pharmacokinetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0166DOI Listing
February 2019
3.218 Impact Factor

Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer.

Pharmacogenomics 2019 Feb 8. Epub 2019 Feb 8.

Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

Aim: The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur-uracil (UFT)-induced liver dysfunction.

Patients & Methods:  A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis.

Results: The first screening revealed the association between five SNPs and UFT-induced hepatic dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0100DOI Listing
February 2019

Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach.

Pharmacogenomics 2019 Jan 6;20(1):21-35. Epub 2018 Dec 6.

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, No. 1277, Jie Fang Road, Wuhan, Hubei province, 430022, PR China.

Aim: The aim of this study was to evaluate tacrolimus population pharmacokinetics and investigate factors that explain tacrolimus variability in adult heart transplant patients.

Methods: A total of 707 tacrolimus concentrations from 107 adult heart transplant patients were included in model development. The effects of demographic, clinical factors and CYP3A5 genotype on tacrolimus clearance were evaluated using a nonlinear mixed-effects modeling. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0116
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0116DOI Listing
January 2019
1 Read

Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Pharmacogenomics 2019 Jan 6;20(1):9-20. Epub 2018 Dec 6.

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Aim: To comprehensively interrogate CYP2D6 by integrating genotyping, copy number analysis and novel strategies to identify CYP2D6*36 and characterize CYP2D6 duplications.

Methods: Genotyping of 16 CYP2D6 alleles, multiplex ligation-dependent probe amplification (MLPA) and CYP2D6*36 and duplication allele-specific genotyping were performed on 427 African-American, Asian, Caucasian, Hispanic, and Ashkenazi Jewish individuals.

Results: A novel PCR strategy determined that almost half of all CYP2D6*10 (100C>T) alleles are actually *36 (isolated or in tandem with *10) and all identified duplication alleles were characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0135DOI Listing
January 2019
1 Read

Foreword: the year at Pharmacogenomics.

Authors:
Sarah Jones

Pharmacogenomics 2019 Jan;20(1)

Commissioning Editor, Pharmacogenomics, Future Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0190DOI Listing
January 2019

Association of endothelin receptor type A rs5333 gene polymorphism with steroid response in Egyptian children with idiopathic nephrotic syndrome.

Pharmacogenomics 2019 Jan 23. Epub 2019 Jan 23.

Department of Medical Microbiology & Immunology, Faculty of Medicine, Assiut university, Assiut, Egypt.

Aim: To investigate ENDRA rs5333 gene polymorphism distribution in idiopathic nephrotic syndrome (INS) and to analyze their association with response to steroid therapy, and biochemical markers of INS.

Subjects & Methods: The PCR-restriction fragment length polymorphism was used to analyze ENDRA rs5333 polymorphism in 100 children with idiopathic nephrotic syndrom (INS) and 100 healthy children. Plasma endothelin-1 were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0175DOI Listing
January 2019
2 Reads

Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.

Pharmacogenomics 2019 Jan 23. Epub 2019 Jan 23.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China.

Aim: The present study aimed to assess the association between IGF2/H19 genetic variants and susceptibility to platinum-based chemotherapy in epithelial ovarian cancer (EOC).

Methods: A total of 43 platinum-resistant (PR) and 138 platinum-sensitive (PS) EOC patients were recruited in our study. Twenty-one polymorphisms in IGF2/H19 locus were genotyped by Sequenom MassARRAY assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0153DOI Listing
January 2019
2 Reads

Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis.

Pharmacogenomics 2019 Jan 23. Epub 2019 Jan 23.

Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, 100034, PR China.

Aim: Genetic polymorphisms may influence the incidence of angiotensin-converting enzyme (ACE) inhibitor-induced cough. This study aims to investigate this association.

Methods: Ten electronic databases and PharmGKB were systematically searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0157DOI Listing
January 2019
1 Read
3.218 Impact Factor

Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.

Pharmacogenomics 2019 Jan 10;20(2):105-111. Epub 2019 Jan 10.

Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

As antiretroviral therapy has become more accessible across the world and coformulations have improved patient compliance; the morbidity and mortality of HIV/AIDS has decreased. However, there is still a substantial gap in knowledge regarding the impact of genetic variation on the metabolism of and response to some of the most commonly prescribed antiretrovirals, including the nucleotide reverse transcriptase inhibitor tenofovir. While it has been scientifically established that tenofovir must be activated to be efficacious against HIV, the enzymes responsible for this activation have not been well characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0140DOI Listing
January 2019
1 Read

Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.

Pharmacogenomics 2019 Jan 10;20(2):85-93. Epub 2019 Jan 10.

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Aim: To study the performance of a clinical pharmacogenetic model for the prediction of nonresponse in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) in combination with other synthetic or biologic disease-modifying anti-rheumatic drugs . This prediction model includes gender, smoking status, rheumatoid factor positivity and four genetic variants in AMPD1 (rs17602729), ATIC (rs2372536), ITPA (rs1127354) and MTHFD1 (rs17850560).

Methods:  A total of 314 RA patients from three Dutch studies were retrospectively included. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0144
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0144DOI Listing
January 2019
6 Reads

Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

Pharmacogenomics 2019 Jan 10. Epub 2019 Jan 10.

Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, PR China.

Aim: To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China.

Materials & Methods: A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0138DOI Listing
January 2019
2 Reads
3.218 Impact Factor

NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p.

Pharmacogenomics 2018 Dec 13. Epub 2018 Dec 13.

Department of Biological Sciences & Technology, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.

Aim: Neurofibromatosis type 1 (NF1) loss confers chemoresistance in multiple cancers. However, the etiology remains largely unknown. Our study aimed to scrutinize the role of NF1 in chemoresistant ovarian cancer and its underlying mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0161DOI Listing
December 2018
4 Reads

Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.

Pharmacogenomics 2019 Jan 12;20(2):113-127. Epub 2018 Dec 12.

Department of Oncology, Faculty of Medicine & Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic.

Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatment resistance, represents a major opportunity, but also a challenge in further research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0073DOI Listing
January 2019
2 Reads

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.

Pharmacogenomics 2019 Jan 6;20(1):37-47. Epub 2018 Dec 6.

Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.

Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD).

Patients & Methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0142
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0142DOI Listing
January 2019
8 Reads

Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.

Pharmacogenomics 2019 Jan 6;20(2):75-83. Epub 2018 Dec 6.

Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds.

Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0148
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0148DOI Listing
January 2019
10 Reads

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

Pharmacogenomics 2019 Jan 6;20(2):95-104. Epub 2018 Dec 6.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA.

Aim:  First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0162
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0162DOI Listing
January 2019
10 Reads

Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator.

Pharmacogenomics 2019 Jan 6;20(2):69-73. Epub 2018 Dec 6.

Department of Pediatrics, USF Health South Tampa Center for Advanced Healthcare, Tampa, FL 33606, USA.

Clonazepam undergoes nitroreduction to 7-amino-clonazepam via CYP3A4/5, followed by acetylation to 7-acetamido-clonazepam via NAT2 enzyme. While no pharmacological activity is attributed to the metabolites of clonazepam, 7-amino-clonazepam has some affinity for the benzodiazepine receptor as a partial agonist for the gamma aminobutyric acid-A receptor and can compete with clonazepam. Interindividual variability in the incidence of adverse events in patients may, in part, be attributable to differences in clonazepam metabolism. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0145
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0145DOI Listing
January 2019
14 Reads

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Pharmacogenomics 2019 Jan 6;20(1):49-68. Epub 2018 Dec 6.

Unit of Clinical Pharmacology & Pharmacogenetics, Department of Clinical & Experimental Medicine, University of Pisa, Italy.

Circulating tumor DNA, circulating tumor cells and tumor-related exosomes may offer new opportunities to provide insights into the biological and clinical characteristics of a neoplastic disease. They represent alternative routes for diagnostic and prognostic purposes, and for predicting and longitudinally monitoring response to treatment and disease progression. Hence, circulating biomarkers represent promising noninvasive tools in the scenario of pancreatic cancer, where neither molecular nor clinical predictors of treatment benefit have been identified yet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0149DOI Listing
January 2019
4 Reads

CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.

Pharmacogenomics 2019 Jan 6;20(1):3-8. Epub 2018 Dec 6.

Department of Pharmaceutical Sciences, School of Pharmacy, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, Puerto Rico.

Warfarin continues to be the mainstay therapy for preventing thrombus formation. Although pharmacogenetic algorithms have shown higher predictability of the optimal warfarin dose and lower occurrence of bleeding episodes, they often do not include ethno-specific genetic variants relevant to non-Europeans. This case report describes a rare missense variant at exon 9 of CYP2C9 (rs202201137; c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0143DOI Listing
January 2019
4 Reads

Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.

Pharmacogenomics 2018 Dec;19(18):1403-1412

Department of Genetics, Physic Anthropology & Animal Physiology, University of the Basque Country, UPV/EHU, Leioa, 48940, Spain.

Aim: Mucositis, linked to methotrexate, daunorubicin or cyclophosphamide, is a frequent childhood acute lymphoblastic leukemia (ALL) therapy side effect. miRNAs regulate the expression of pharmacokinetic/pharmacodynamic pathway genes. SNPs in miRNAs could affect their levels or function, and affect their pharmacokinetic/pharmacodynamic pathway target genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0113DOI Listing
December 2018
1 Read

Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.

Pharmacogenomics 2018 Dec 16;19(18):1383-1394. Epub 2018 Nov 16.

Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA.

Aim: This study tests whether polygenic risk scores (PRSs) for nicotine metabolism predict smoking behaviors in independent data.

Materials & Methods: Linear regression, logistic regression and survival analyses were used to analyze nicotine metabolism PRSs and nicotine metabolism, smoking quantity and smoking cessation.

Results: Nicotine metabolism PRSs based on two genome wide association studies (GWAS) meta-analyses significantly predicted nicotine metabolism biomarkers (R range: 9. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0081
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0081DOI Listing
December 2018
9 Reads

Genetic polymorphism contributes to I radiotherapy-induced toxicities in patients with differentiated thyroid cancer.

Pharmacogenomics 2018 Nov 16;19(17):1335-1344. Epub 2018 Oct 16.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China.

Aim: To investigate the association between SNPs in DNA damage response pathways and toxicities following I radiotherapy of differentiated thyroid cancer (DTC). Materials & methods: We identified 22 functional SNPs of genes in DNA damage response pathways. MassArray was used to sequence SNP genotypes in 203 DTC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0070DOI Listing
November 2018
2 Reads

Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.

Pharmacogenomics 2018 Nov;19(16):1269-1284

Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, AB, AN T2N 1N4, Canada.

Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. Read More

View Article

Download full-text PDF

Source
https://www.researchgate.net/publication/24239584_Depression
Web Search
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0099
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0099DOI Listing
November 2018
7 Reads
3.220 Impact Factor

Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:
Jason H Karnes

Pharmacogenomics 2018 Dec 6;19(18):1413-1422. Epub 2018 Nov 6.

Department of Pharmacy Practice & Science, University of Arizona College of Pharmacy, Tucson, AZ 85721, USA.

Heparin-induced thrombocytopenia (HIT) is a life-threatening, immune-mediated adverse reaction to heparin anticoagulants. The inability to predict HIT represents a considerable liability associated with heparin administration. Genetic studies of HIT are challenging due to the scarcity of true HIT cases, potential for misclassification, and many environmental risk factors. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0147
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0147DOI Listing
December 2018
18 Reads

Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions.

Pharmacogenomics 2018 Dec 6;19(18):1423-1435. Epub 2018 Nov 6.

Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo 14049-900, Brazil.

Endothelial nitric oxide synthase (NOS3) is a key enzyme responsible for nitric oxide (NO) generation in the vascular endothelium. Endothelial dysfunction is characterized by reduced NO production, and is a hallmark of cardiovascular diseases. Drugs with cardiovascular action may activate NOS3 and result in NO release and vasodilation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0098DOI Listing
December 2018
1 Read

Analysis of outpatient HER2 testing in New York state using the statewide planning and research cooperative system.

Pharmacogenomics 2018 Dec 6;19(18):1395-1401. Epub 2018 Nov 6.

Department of Pharmaceutical Sciences, The School of Pharmacy & Pharmaceutical Sciences, The State University of New York at Buffalo, 470, Kapoor Hall, Buffalo, NY 14214, USA.

Aim: HER2 testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib and neratinib. There is a paucity of reports describing the utilization rates of HER2 testing in large outpatient populations.

Methods: The Statewide Planning and Research Cooperative System (SPARCS) was used to examine HER2 testing across the state of New York (USA) during the 2012-2016 period. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0120
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0120DOI Listing
December 2018
6 Reads

Integrating metabolomics with genomics.

Authors:
Amalio Telenti

Pharmacogenomics 2018 Dec 6;19(18):1377-1381. Epub 2018 Nov 6.

Translational Institute & Department of Integrative Structural & Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0155
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0155DOI Listing
December 2018
8 Reads

Rosuvastatin pharmacogenetics in African populations.

Pharmacogenomics 2018 Dec 6;19(18):1373-1375. Epub 2018 Nov 6.

Department of Pathology, Division of Human Genetic, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0168DOI Listing
December 2018
1 Read
3.220 Impact Factor

No association between G1359A CB1 polymorphisms and pain in young northeastern Mexicans.

Pharmacogenomics 2018 Nov 29;19(16):1251-1258. Epub 2018 Oct 29.

Facultad de Ciencias Químicas, Universidad Autonoma de Nuevo Leon, Pedro de Alba S/N, Ciudad Universitaria, San Nicolás de los Garza, Nuevo Leon, CP 66455, Mexico.

Aim: Recent studies show an association between the endocannabinoid system and pain. In this study, we analyzed the association between two CNR1 gene polymorphisms and pain perception in a northeast Mexican population.

Methods: Genotypic and allelic frequencies were obtained for both polymorphisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0125DOI Listing
November 2018
1 Read

Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development.

Pharmacogenomics 2018 Nov 23;19(17):1303-1310. Epub 2018 Oct 23.

Centre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, Greece.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0141
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0141DOI Listing
November 2018
2 Reads

Novel motif of variable number of tandem repeats in TPMT promoter region and evolutionary association of variable number of tandem repeats with TPMT*3 alleles.

Pharmacogenomics 2018 Nov 22;19(17):1311-1322. Epub 2018 Oct 22.

Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.

Aim: SNPs in the gene for TPMT exemplify one of the most successful translations of pharmacogenomics into clinical practice. This study explains the correlation between common SNPs and variable number of tandem repeats (VNTR) in promoter of the gene.

Materials & Methods: We determined VNTR polymorphisms, as well as TPMT*2 and TPMT*3 SNPs and TPMT activity in Slovenian and Italian individuals and lymphoblastoid cell lines. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0123
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0123DOI Listing
November 2018
10 Reads

Implementing a personalized medicine program in a community health system.

Pharmacogenomics 2018 Nov 22;19(17):1345-1356. Epub 2018 Oct 22.

Office of the CEO, Mission Health, 9 Vanderbilt Park Drive, Asheville, NC 28803, USA.

The implementation of a de novo personalized medicine program in a rural community health system serving an underserved population is described. Focusing on the safe use of drugs impacted by genetic variations in the non-oncology setting, we first addressed drug-gene pairs designated by the US FDA in black-box warnings (codeine, clopidogrel, abacavir, carbamazepine). The program's first success was a policy change to remove codeine from the pediatric formulary, rather than a testing recommendation. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0130
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0130DOI Listing
November 2018
10 Reads

Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Pharmacogenomics 2018 Nov 22;19(17):1357-1371. Epub 2018 Oct 22.

Department of Neurology, School of Medicine, University of Alabama at Birmingham, AL 35294, USA.

Despite the introduction of direct acting oral anticoagulants, warfarin remains the most commonly prescribed oral anticoagulant. However, warfarin therapy is plagued by the large inter- and intrapatient variability. The variability in dosing fueled research to identify clinical and genetic predictors and develop more accurate dosing algorithms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0146DOI Listing
November 2018
3 Reads

Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients.

Pharmacogenomics 2018 Nov 22;19(17):1323-1334. Epub 2018 Oct 22.

Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, Guangdong, PR China.

Aim: To evaluate genetic variants affecting mycophenolic acid (MPA) metabolism in Chinese renal transplant recipients.

Methods:  Total 11 SNPs of UGT1A9, UGT1A8, UGT2B7, ABCC2, ABCG2 and SLCO1B3 were genotyped in 408 Chinese renal transplant recipients. Associations between SNPs and MPA concentration/dose ratio (C/D) were analyzed using different genetic models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0114DOI Listing
November 2018
5 Reads
3.220 Impact Factor

Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier?

Pharmacogenomics 2018 Nov 18;19(16):1231-1233. Epub 2018 Oct 18.

Department of Pediatrics, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital, University of Missouri Kansas City School of Medicine, Kansas City, MO 64152, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0132DOI Listing
November 2018
1 Read

How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?

Pharmacogenomics 2018 Nov 18;19(16):1285-1297. Epub 2018 Oct 18.

Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.

Several polymorphisms have been identified in ABCB1, the gene encoding for the P-glycoprotein. This transporter alters the pharmacokinetics or effectiveness of drugs by excreting them from cells where it is expressed (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0101DOI Listing
November 2018
1 Read

Precision HIV care: responding to old questions and meeting new challenges.

Pharmacogenomics 2018 Nov 16;19(17):1299-1302. Epub 2018 Oct 16.

Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0126
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0126DOI Listing
November 2018
3 Reads

RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Pharmacogenomics 2018 Nov 16;19(16):1235-1249. Epub 2018 Oct 16.

Department of Pediatrics, State University of New York at Buffalo, NY 14203, USA.

Aim: To examine the genetic differences between subjects with statin-associated muscle symptoms and statin-tolerant controls.

Materials & Methods: Next-generation sequencing was used to characterize the exomes of 76 subjects with severe statin-associated muscle symptoms and 50 statin-tolerant controls.

Results: 12 probably pathogenic variants were found within the RYR1 and CACNA1S genes in 16% of cases with severe statin-induced myopathy representing a fourfold increase over variants found in statin-tolerant controls. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0106
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0106DOI Listing
November 2018
4 Reads

Pharmacogenetic content of commercial genome-wide genotyping arrays.

Pharmacogenomics 2018 Oct 1;19(15):1159-1167. Epub 2018 Oct 1.

Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre, 5000 Belanger Street, Montreal, H1T 1C8, Canada.

Aim: We have evaluated the pharmacogenetic content of commercial human genome-wide genotyping arrays, as it is a critical determinant to enabling pharmacogenomic discoveries.

Methods: Using bioinformatics approaches, we assessed 27,811 genetic variants in 3146 genes for their presence in 18 Illumina and 15 Affymetrix genome-wide arrays.

Results: The pharmacogenetic content of the arrays varied greatly. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2017-0129
Publisher Site
http://dx.doi.org/10.2217/pgs-2017-0129DOI Listing
October 2018
3 Reads

Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.

Pharmacogenomics 2018 Oct 14;19(15):1147-1150. Epub 2018 Sep 14.

Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0124
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0124DOI Listing
October 2018
13 Reads

Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study.

Pharmacogenomics 2018 Oct 12;19(15):1169-1179. Epub 2018 Sep 12.

Department of Psychiatry, University of California, San Diego, CA 92093, USA.

Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.

Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.

Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0088DOI Listing
October 2018
3 Reads

Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients.

Pharmacogenomics 2018 Oct 12;19(15):1195-1202. Epub 2018 Sep 12.

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.

Aim: To study the effects of clinical and genetic factors on the phenprocoumon dose requirement in pediatric patients and to develop a dosing algorithm.

Methods: Pediatric patients who used phenprocoumon were invited to participate in a retrospective follow-up study. Clinical information and genotypes of genetic variations in CYP2C9, VKORC1, CYP4F2, CYP2C18 and CYP3A4 were collected and tested with linear regression for association with phenprocoumon dose requirement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0095DOI Listing
October 2018
2 Reads

Using genomics to guide treatment for glioblastoma.

Pharmacogenomics 2018 Oct 11;19(15):1217-1229. Epub 2018 Sep 11.

Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA.

Glioblastoma has been shown to have many different genetic mutations found both within and between tumor samples. Molecular testing and genomic sequencing has helped to classify diagnoses and clarify difficult to interpret histopathological specimens. Genomic information also plays a critical role in prognostication for patients, with IDH mutations and MGMT methylation having significant impact of the response to chemotherapy and overall survival of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0078DOI Listing
October 2018
2 Reads
3.220 Impact Factor

Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.

Pharmacogenomics 2018 Nov 10;19(16):1259-1268. Epub 2018 Sep 10.

Department of Clinical Oncology, Karolinska University Hospital, SE171-76 Stockholm, Sweden.

Aim: This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment.

Patients & Methods: In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0080
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0080DOI Listing
November 2018
9 Reads

Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Pharmacogenomics 2018 Oct 10;19(15):1203-1216. Epub 2018 Sep 10.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The AHA/ACC recommends against routine pharmacogenetic testing for clopidogrel because no randomized controlled trials have demonstrated that testing improves patients' outcomes. However the AHA/ACC and the National Comprehensive Cancer Network (NCCN) recommend other pharmacogenetic tests in the absence of randomized controlled trials evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219446PMC
October 2018
1 Read

Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.

Pharmacogenomics 2018 Oct 7;19(15):1181-1193. Epub 2018 Sep 7.

Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, QC, H3T1C5, Canada.

Aim: To identify genetic markers associated with vincristine-induced peripheral neuropathy (VIPN) in childhood acute lymphoblastic leukemia.

Patients & Methods: Whole-exome sequencing data were combined with exome-wide association study to identify predicted-functional germline variants associated with high-grade VIPN. Genotyping was then performed for top-ranked signals (n = 237), followed by validation in independent replication group (n = 405). Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0093
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0093DOI Listing
October 2018
15 Reads